Revenue beat, margin miss, semiconductor qualified—hold pending margin recovery

On paper, Tatva had a record quarter: revenue of ₹167.1 crore grew at 42.9% year-over-year, crushing the 25–30% guidance handed out in the prior call. But the margin miss is the story that matters. EBITDA came in at 19.3%, 100 basis points below the reaffirmed 20–22% target. Management blamed rapid raw material cost inflation and a slow ramp on passing those costs through to customers. That lag—combined with a Middle East raw material shortage that knocked Electrolyte Salts revenue down 52% quarter-on-quarter—is why the company held guidance rather than raising it.

Cost inflation was 'too rampant and came at short notice,' per management. Price increases began only 40–50 days before the call, leaving a lag where input costs had already risen. Electrolyte Salts revenue fell to ₹6.3 crore from ₹13.1 crore in Q4 FY26—a 2-month production loss because of a shortage of key raw materials from the Middle East. The company absorbed those headwinds while pushing organic volume growth across Phase Transfer Catalysts (+47% YoY), Structure Directing Agents (+47% YoY), and Pharma Intermediates (+25% YoY). Adjusted for the margin miss, organic profit quality is solid, not exceptional.

Three updates matter for the medium term. First, semiconductor qualification: the company's first plant-scale batch was delivered to a customer and commercially approved. This validates R&D and manufacturing capability but is a milestone, not revenue. The path to volume sales is 3–4 more plant-scale trials over 2 years; real volume isn't expected until late 2028 at the earliest. Second, pharma molecule ramp: one intermediate commenced production in Q1; the company expects ₹70–80 crore incremental revenue from three molecules by end of FY27, scaling to ₹200 crore at full utilization. The demand signal is real. Third, supply disruption and strategy shift: Middle East raw material shortage caused the Electrolyte Salts plunge; separately, a Chinese price collapse in glymes ($4.6 to $2.1 per unit in 30 days) made capacity expansion uneconomical, so management repurposed equipment for supercapacitor electrolyte instead. That's tactical pivot, not confidence loss, but it underscores external volatility.

The market loved the result: the stock rallied +20% on day 1, holding +16.58% by day 3 and +20.61% by day 5. That conviction is notable. However, the technicals are now stretched. The stock is trading at ₹1,788.2, up 70.3% from its 52-week low of ₹1,050 and only 2.53% below its all-time high. The RSI is 73.6, signaling overbought, and volume has declined. FII ownership ticked down 35 basis points quarter-on-quarter to 3.82%, and domestic institutions also trimmed 34 basis points to 2.99%. The post-result pop held, which suggests real conviction in the long-term story, but price momentum is fading and institutional inflows have stalled. A valuation reset or profit-taking is plausible if near-term execution (margin recovery, Electrolyte Salts ramp) disappoints.